Braves, Chris Sale Agree To Two-Year Deal
The Braves and left-hander Chris Sale have agreed to a new deal, which will pay him $38MM over the next two years. The Wasserman client will earn $16MM in 2024 and $22MM in 2025 and there’s also an $18MM club option for 2026. Sale was already under contract via an extension he previously signed with the Red Sox but this will overwrite that.
Sale was acquired from the Red Sox last week, in a trade that sent Vaughn Grissom to Boston. The Sox also included $17MM to cover the remainder of Sale’s contract, a five-year, $145MM extension he and the Red Sox signed in 2019. As part of that deal, Sale was set to make $27.5MM in 2024, though $10MM of that was deferred until 15 years in the future. With the $17MM coming from the Sox, Atlanta was only going to be paying him $500K. There was also a $20MM club option for 2025.
As part of this new deal, Sale’s $16MM salary will be pretty close to the non-deferred money he was going to make in 2024. He will no longer have that deferred $10MM payment down the road, but he will have $22MM locked in for the 2025 season. That gives him some extra security in the event of more health problems cropping up this year. Sale pitched less than 50 total innings over the 2020-2022 period, mostly due to Tommy John surgery but also due to other ailments. Last year, he was able to toss 102 2/3 frames but a stress reaction in his shoulder blade kept him out of action for over two months. Any further health issues would have perhaps given the club some hesitation about picking up the 2025 option but Sale has now locked in a notable salary for next year.
For Atlanta, this is a show of faith in the soon-to-be-35-year-old. They could have simply employed Sale for 2024 and then walked away if things didn’t go well, with the club option there to keep him around if he had a strong campaign for his new club. But they have now committed themselves to at least two years of Sale, with the club option now kicked down the road to 2026. As mentioned, Sale hasn’t been fully healthy in the past four years and even had some issues before that. Some shoulder and elbow issues kept him around 150 innings in 2018 and 2019, meaning his last fully healthy campaign was 2017.
Back then, Sale was one of the best pitchers in the league, finishing that 2017 season with a 2.90 ERA. Last year, he wasn’t quite as dominant, with a 4.30 at the end of the season. The peripherals were a bit better, however, with a 29.4% strikeout rate and 6.8% walk rate that were both strong.
Despite that fairly solid bounceback season, it’s obviously a gamble to bet on a pitcher that has been hurt so much, locking him up for his age-35 and age-36 seasons. But the club has a decent amount of rotation uncertainty going forward. Max Fried is entering his final year of club control while Charlie Morton is one year from free agency as well. Morton has flirted with retirement before and is going into his age-40 season, making it possible he won’t be back in 2025.
Prior to this deal, Sale was a potential to depart as well, depending on the outcome of the club option. Now that he’s under contract for 2025, he can be pencilled into next year’s rotation next to Spencer Strider. The club will still have to fill out the rest of the rotation, but perhaps internal options like Bryce Elder, AJ Smith-Shawver and Hurston Waldrep will have taken steps forwards between now and then.
There’s also the competitive balance tax to consider. Under the current collective bargaining agreement, a player’s CBT hit is recalculated when he is traded to reflect what remains of the contract. That means that Sale was going to have a $27.5MM CBT hit prior to this deal, with the Sox absorbing $17MM of that. But that will now drop to $19MM, leaving just $2MM on Atlanta’s CBT ledger this year but $19MM next year. Going into today, the club’s CBT figure was at $276MM, per Roster Resource. That’s right against the third tax threshold of $277MM, which is a notable line to cross. Clubs that go over the third threshold have their top pick in the next draft pushed back by 10 slots, in addition to an increased tax rate. By lowering Sale’s CBT hit, the club will have a bit more breathing room to make more moves, either now or during the season.
Ultimately, it’s a pact that works for both sides. Atlanta gets a bit more luxury tax space and also, hopefully, a better rotation outlook in 2025 and maybe even 2026. Sale, meanwhile, locks in some future earnings to guard against any continued health issues.
MLBTR Podcast: Yamamoto Fallout, the Sale/Grissom Trade and Transaction Roundup
The latest episode of the MLB Trade Rumors Podcast is now live on Spotify, Apple Podcasts, and wherever you get your podcasts! Make sure you subscribe as well! You can also use the player at this link to listen, if you don’t use Spotify or Apple for podcasts.
This week, host Darragh McDonald is joined by Anthony Franco of MLB Trade Rumors to discuss…
- The Dodgers signing Yoshinobu Yamamoto and what’s next for the teams that missed (0:55)
- Red Sox agreed to terms with Lucas Giolito and then traded Chris Sale to the Braves for Vaughn Grissom (7:50)
- The Royals spreading money around to various players (16:10)
- The Blue Jays sign Kevin Kiermaier and Isiah Kiner-Falefa (20:25)
- Mariners sign Mitch Garver (26:05)
- Reds sign Frankie Montas (28:35)
Check out our past episodes!
- Tyler Glasnow, Jung Hoo Lee, D-Backs’ Signings and the Braves’ Confusing Moves – listen here
- Shohei Ohtani, Juan Soto and Deferred Money – listen here
- Winter Meetings, Ohtani Secrecy, and the Mariners Shedding Salary – listen here
The podcast intro and outro song “So Long” is provided courtesy of the band Showoff. Check out their Facebook page here!
Braves, Red Sox Trade Chris Sale For Vaughn Grissom
The Braves and Red Sox have agreed to a major trade, as left-hander Chris Sale will head to Atlanta in exchange for infield prospect Vaughn Grissom, ESPN’s Jeff Passan reports. The Sox will also include $17MM in the deal to help cover Sale’s $27.5MM salary for the 2024 season, as per the Boston Globe’s Alex Speier. Sale had a full no-trade clause that he has waived to facilitate the move.
The surprising move ends Sale’s tumultuous run in Boston after seven years and six seasons, as Sale missed all of the 2020 campaign. After acquiring Sale as part of a blockbuster deal with the White Sox in December 2016, Sale pitched brilliantly in his first two seasons at Fenway, twice finishing in the top four in AL Cy Young Award voting and playing a big role in Boston’s World Series title in 2018.
Since 2019 was the last year of Sale’s previous contract, the Red Sox were aggressive in locking up their ace, signing him to a five-year, $145MM extension covering the 2020-24 seasons, with a $20MM club option for the 2025 campaign. Unfortunately, this extension has proven to be a big misfire, as Sale started to run into injury problems even late in the 2018 campaign. He was shut down in August 2019 with elbow inflammation and received a PRP injection, yet that elbow issue was only the harbinger for the Tommy John surgery that cost Sale his entire 2020 season and most of his 2021 campaign.
The bad injury luck continued over the last two seasons, as Sale was sidelined by a wide array of maladies including a stress reaction in his ribs, a fractured finger, a broken wrist (suffered in a bicycle accident), and a stress reaction in his shoulder blade. Sale tossed only 48 1/3 innings total in 2021-22, while rebounding to some extent to pitch 102 2/3 frames last season.
Sale’s 93.9mph fastball velocity in 2023 slightly topped his career average, while his strikeout, walk, and hard-hit ball rates were all well above the league average. While the southpaw may never get back to his past elite form, Sale’s 2023 performance at least indicated that he still has a good deal left in the tank as he enters his age-35 season, provided that he can just stay on the field.
This is exactly what the Braves are counting on from Sale as a third or even a fourth starter, behind Max Fried, Spencer Strider, and Charlie Morton in the team’s rotation. President of baseball operations Alex Anthopoulos is counting in Sale’s upside to bolster the pitching staff, and Atlanta’s collection of younger arms (AJ Smith-Shawver, Dylan Dodd, Huascar Ynoa, Darius Vines, and top prospect Hurston Waldrep) and swingman Reynaldo Lopez can provide extra depth should Sale or anyone else in the rotation need time on the injured list.
In typical Anthopoulos fashion, this particular trade came out of nowhere, even if the Braves were known to be looking for some pitching help. Atlanta made a strong bid for Aaron Nola before he re-signed with the Phillies, and such free agent and trade targets as Tyler Glasnow, Dylan Cease, Sonny Gray, and Seth Lugo were also linked to the Braves on the rumor mill.
Because Sale’s extension the Red Sox contained $10MM of deferred money per season, he’ll cost the Braves merely $500K in actual salary in 2024. Even without the deferral involved, a one-year, $10.5MM deal for Sale as a free agent would’ve been a reasonable or even a slight bargain price for a pitcher with his track record. It could perhaps be argued that the Braves might have been better off finding such a pitcher on the free agent market rather than trade away a promising young player like Grissom, but it is also fair to note that such a rotation upgrade might not have existed at a $10.5MM price tag. Or, dealing for a pitcher like Cease, Corbin Burnes, Shane Bieber, or other still-available trade candidates might’ve cost Atlanta lot more than only Grissom.
Sale’s $20MM club option for 2025 shouldn’t be discounted either, as the Braves might consider exercising that option if Sale pitched well. The $20MM figure matches what Morton is earning this season, and since Morton has flirted with retirement over the last few years, Sale could potentially step in as Atlanta’s veteran rotation arm if Morton does hang up his cleats next winter. Sale’s $20MM club option is actually a vesting option that becomes guaranteed if he finishes the year healthy, and finished in the top 10 in NL Cy Young Award voting.
Anthopoulos and team chairman Terry McGuirk weren’t kidding last November when they said that the Braves planned to keep increasing payroll. The Braves’ $203MM Opening Day payroll from 2023 was already a club record, and Roster Resource now projects a payroll just shy of $241MM for the 2024 squad. After topping the luxury tax barrier for the first time in 2023, the Braves’ estimated $280MM tax number now soars over the third penalty tier of $277MM, so they’ll face increasingly hefty overages as second-time payors. Passing the third tier means that Atlanta’s top pick in the 2024 draft will now drop 10 spots, and they’ll face the standard tax penalties related to qualified free agents and the international bonus pool.
This doesn’t appear to be much of a deterrent for an Atlanta club that has been swimming in extra revenues since the opening of Truist Park and its neighboring ballpark village project known as The Battery. The Braves have used this money to lock up several members of its roster on contract extensions, and this young core has already delivered the 2021 World Series championships and six straight NL East crowns.
The outlook hasn’t been as rosy at Fenway Park, as the Red Sox have been very inconsistent since that 2018 title. On the heels of consecutive last-place finishes in the AL East, Craig Breslow replaced Chaim Bloom as the team’s chief baseball officer, and Breslow now has his first true blockbuster trade as a front office executive.
Starting pitching has been a known need for the Red Sox all winter, and Boston just signed Lucas Giolito yesterday to help address the rotation mix. While moving Sale diminishes from the number of available arms, the trade does free up some money to help make other moves, and the Sox simply might’ve wanted a more reliable starting pitching option than the injury-plagued Sale. Plus, adding six years of team control over a promising player like Grissom is a nice return for the Sox at the cost of $17MM.
Grissom immediately fills Boston’s need for second base help. An 11th-round pick for Atlanta in the 2019 draft, Grissom has torn up minor league pitching during his four seasons in the Braves’ farm system and quickly got himself on the radar for a big league call-up. Grissom hit .291/.353/.440 over 156 plate appearances in 2022, though followed up with a more modest .659 OPS in just 80 PA last season. Given a chance at the everyday shortstop job, Grissom fell behind Orlando Arcia on the depth chart, and ultimately spent most the season at Triple-A since the Braves wanted him to play regularly rather than ride the bench.
Grissom has spent much of his minor league career as a shortstop, yet there has been some question about his long-term viability at the position. Moving to second base or third base was difficult on a Braves team with Ozzie Albies and Austin Riley already in place, so Grissom had been getting some reps as an outfielder as a possible candidate to fill the club’s left field vacancy. However, the acquisition of Jarred Kelenic from the Mariners also seemed to close that door.
No such position blocks exist in Boston, as the Red Sox might well just install Grissom as their Opening Day second baseman. He fits Breslow’s preferred add of a right-handed hitter, and Grissom’s glovework could or should work out well at the less-demanding second base position. Getting Grissom in the fold could now relegate Enmanuel Valdez, Pablo Reyes, or Rob Refsnyder to pure backup duty or perhaps even as trade chips, while Ceddanne Rafaela now looks even likelier to be used as an outfielder (and Rafaela might yet be a trade candidate himself).
Photo courtesy of USA Today Sports Images
Alex Anthopoulos, Craig Breslow Discuss Chris Sale Trade
The Braves and Red Sox got together on a major trade earlier today where Boston swapped left-hander Chris Sale and cash considerations to Atlanta in exchange for infielder Vaughn Grissom. In the aftermath of the deal’s announcement, Braves president of baseball operations Alex Anthopoulos and Red Sox chief baseball officer Craig Breslow both spoke to reporters about the deal and what’s next for their organization as 2023 comes to a close.
Anthopoulos spoke glowingly of Sale in the aftermath of the deal, describing him to reporters (including Justin Toscano of the Atlanta Journal-Constitution) as a “playoff-caliber starter” while noting that adding such a pitcher to the club’s rotation was a major goal for the Braves this offseason. With right-hander Kyle Wright having undergone shoulder surgery and been shipped to Kansas City earlier this offseason, the club had little certainty behind its front-of-the-rotation duo of Spencer Strider and Max Fried.
Veteran righty Charlie Morton figured to slot into the #3 spot in the rotation, but posted the highest full-season walk rate of his career in 2023 and celebrated his 40th birthday last month. Meanwhile, youngster Bryce Elder started the season strong but faded down the stretch with a 5.49 ERA across his final 15 starts. The addition of Sale, a seven-time All Star who posted a 3.16 ERA across his final 15 starts last season, adds an arm with potentially elite upside to the club’s mix while also bolstering the club’s overall pitching depth to help make up for the departure of Wright. As noted by The Athletic’s David O’Brien, Anthopoulos made clear that Sale is “locked” into the club’s rotation for 2024 alongside Fried, Strider, and Morton.
Of course, it can’t be ignored that Sale has managed just 31 starts over the past four years due to injuries, including Tommy John surgery. Anthopoulos acknowledged the injury concerns that come with adding the veteran lefty, but noted that “anyone you acquire, there’s risk” while also adding that “it was a shot we wanted to take” thanks in part to Anthopoulos’s strong belief in Sale’s ability and makeup.
“We think he’s an absolute perfect fit with our group,” Anthoupolos said, “We’ll get to know him and we’ll do everything we can to put him in the best position to stay healthy and have success.”
When discussing the club’s plans for the remainder of the offseason, Anthopolous remained vague, noting that the offseason has no set end point and that moves continue to happen even into Spring Training. He went on to note that the club will “keep an open mind” for the remainder of the offseason. It wouldn’t be a shock if the club was done with the heavy-lifting of its offseason at this point, as they’ve already bolstered the pitching staff with Reynaldo Lopez and traded for a starting left fielder in Jarred Kelenic in addition to the acquisition of Sale.
On the other end of the trade, Breslow called moving on from Sale “a really tough, tough decision” when speaking to reporters (including Alex Speier of the Boston Globe), particularly considering Sale’s legacy as a key piece of the club’s 2018 World Series team. At the same time, Breslow lauded Grissom for his “really strong right-handed bat” while also noting that he figures to remain under club control for the next six seasons.
“I’ve talked long about the exciting emerging core of players around whom we want to build,” Breslow said, “…we certainly count Vaughn in that group.”
Though Breslow noted that Grissom has the versatility to play all over the field, he made clear that he views the 22-year-old as the club’s everyday second baseman. That would seemingly leave veteran infielder Trevor Story poised to return to shortstop on a full-time basis. Story struggled in 43 games last season after returning from UCL surgery over the summer, but prior to that injury had a long track record as a quality, two-way shortstop that earned him a six-year, $140MM deal with the Red Sox prior to the 2022 season.
One curious aspect of the deal from Boston’s perspective is that the club has made adding to its starting rotation an explicit goal throughout the offseason, and parting ways with Sale, who in spite of his recent injuries arguably remained their highest-ceiling starter, creates an even bigger hole in their starting five. Breslow emphasized (as relayed by Pete Abraham of the Boston Globe) that the club still plans to add to its rotation even after yesterday’s signing of Lucas Giolito, and that the club views both free agency and the trade market as potential avenues for a deal. Speier relays that Breslow noted the importance of the club being willing to part with prospects in order to acquire “quality, controllable starting pitching.”
The club has recently been linked to a reunion with left-hander James Paxton while also frequently being connected to top remaining rotation arms such as Jordan Montgomery and Shota Imanaga. Of course, there are plenty of other players still available who could represent an upgrade for the club’s rotation including Marcus Stroman and Yariel Rodriguez in free agency or Dylan Cease and Shane Bieber on the trade market. A trade would likely become an even more attractive route for adding to the rotation if the club’s reported pursuit of outfielder Teoscar Hernandez winds up successful, as it would add an everyday bat to the outfield mix and make the likes of Wilyer Abreu and Ceddanne Rafaela easier to part with in trade.
AL East Notes: Verdugo, Sale, Misiewicz, Hamilton, Mountcastle, Cimber
Alex Verdugo‘s name surfaced in trade rumors around the deadline, with at least one unknown AL team reportedly having interest in the Red Sox outfielder. WEEI.com’s Rob Bradford reports that the Yankees and Astros had some talks with the Sox about Verdugo, but naturally no deal was completed. The Astros instead focused on adding pitching (Justin Verlander and Kendall Graveman) at the deadline but have gotten a lineup boost from Michael Brantley‘s return from the injured list, while the Yankees only made a couple of lower-level bullpen additions. While it has been an inconsistent season for Verdugo, New York’s decision to not add any batting help backfired, as the near team-wide hitting slump in August sunk the Yankees’ playoff chances.
Boston’s deadline strategy over the last two seasons has been the subject of criticism, and undoubtedly factored into the team’s decision to fire chief baseball officer Chaim Bloom earlier this week. With the Red Sox on the outskirts of the wild card race in both seasons, Bloom didn’t pursue a clear selling-or-buying direction in either year, opting for a more cautious approach rather than going all in on contending or moving any high-profile names.
Most surprisingly, Bradford also reported that Bloom turned down an unknown club’s offer to acquire Chris Sale and all of the remaining money on Sale’s contract at the 2022 deadline. “The Red Sox wanted better players than were offered and no deal was done,” Bradford writes, yet an argument can certainly be made that getting Sale’s salary off the books would’ve represented enough of a win for the Sox that the player return might have been a secondary concern. Sale is making $27.5MM this season and in 2024, with a $20MM club option for 2025 that looks very unlikely to be exercised given how Sale has struggled with injuries over the last few seasons.
Here’s more from around the AL East…
- The Yankees placed left-hander Anthony Misiewicz on the seven-day concussion IL today while reinstating righty Ian Hamilton from the 15-day IL. Misiewicz was carted off the field yesterday after being struck in the head with a Ji Hwan Bae line drive, but manager Aaron Boone told the YES Network today that Misiewicz was released from hospital and “all things considered, I think he’s doing pretty well.” More will be known once Misiewicz undergoes further testing, and while there is no timetable for concussion-related symptoms, it would seem like Misiewicz’s season might be over. The southpaw has a 9.00 ERA over 11 total innings with the Diamondbacks, Tigers, and Yankees this season, and Friday’s game marked Misiewicz’s third game in the pinstripes since being claimed off waivers from Detroit back in July. Hamilton returns after a minimal 15-day absence due to a groin strain.
- Ryan Mountcastle isn’t in the Orioles‘ lineup today, and hasn’t played since leaving Wednesday’s game due to left shoulder discomfort. Manager Brandon Hyde told MASNsports.com’s Roch Kubatko and other reporters that Mountcastle was feeling “just okay” when trying to take some swings yesterday, and was hopeful Mountcastle might be available to pinch-hit in today’s game.
- Blue Jays reliever Adam Cimber will start a Triple-A rehab assignment today, manager John Schneider told The Athletic’s Kaitlyn McGrath and other reporters. A pair of shoulder-related injuries have limited Cimber to 20 2/3 innings this season, and he hasn’t pitched due to June 18 due to an impingement in his right shoulder. This lengthy stint on the 60-day IL means that Cimber will need a few rehab games to ramp up, but he should be able to return to the Jays’ bullpen before the season is through. After posting a 2.53 ERA over 142 1/3 innings with the Marlins and Blue Jays in 2021, Cimber has only a 7.40 ERA this year, though his shoulder issues have likely contributed to those struggles.
Red Sox Reinstate Chris Sale From 60-Day Injured List
The Red Sox announced that they have reinstated left-hander Chris Sale from the 60-day injured list, with fellow lefty Brandon Walter optioned in a corresponding move. The 40-man roster previously had a vacancy but is now full. Chris Cotillo of MassLive reported the moves prior to the official announcement. Sale will start tonight’s game against the Tigers.
Sale, 34, was once one of the best pitchers in the majors but his health has been the primary focus in recent years. He required Tommy John surgery in 2020, wiping out that season and most of 2021 as well. In 2022, a stress reaction in his ribs kept him out until July. He returned but fractured a finger when he was struck by a comebacker. While on the injured list for that ailment, he broke his wrist in a bicycle accident.
Here in 2023, it was relatively smooth sailing for a while. He tossed 59 innings over 11 starts, allowing 4.58 earned runs per nine innings but he probably deserved better. He struck out 28.5% of batters faced and walked 6%, but his .315 batting average on balls in play and 69.4% strand rate were both a bit on the unlucky side. Metrics like his 3.69 FIP and 3.47 SIERA painted a rosier picture of his season than his ERA.
In early June, he was placed on the 15-day injured list due to shoulder inflammation, though he was later moved to the 60-day IL with his condition described as a stress reaction in his shoulder blade. That has kept him out of action until now, just a bit beyond the 60-day minimum.
What the Sox will get from Sale at this point remains to be seen. His results earlier in the year were decent, but he’s already pitched more innings than in any season since 2019. Perhaps he will run into workload concerns, though his rotation mate James Paxton shows that’s not necessarily the case. The latter has thrown 80 1/3 innings this year with a 3.36 ERA after missing almost all of the previous three campaigns. Sale has one more guaranteed year remaining on his extension with a $27.5MM salary for 2024 and a $20MM club/vesting option for 2025.
Sale and Paxton figure to hold down two rotation spots for now, with Brayan Bello, Nick Pivetta and Kutter Crawford in the other three. Garrett Whitlock and Tanner Houck are both on rehab assignments right now and could factor into that mix soon, though manager Alex Cora recently said there’s “a good chance” Whitlock will be used as a multi-inning reliever upon his return.
East Notes: Red Sox, Verdugo, Severino, Narvaez, Perez
The Red Sox issued a positive update regarding the status of right-hander Garrett Whitlock today, with manager Alex Cora (as relayed by MassLive’s Christopher Smith) indicating that he’s poised to begin a minor league rehab assignment next week. Whitlock has been on the 15-day injured list due to a bone bruise in his elbow for just over a month. Meanwhile, both right-hander Tanner Houck and left-hander Chris Sale could also be nearing returns, with Houck expected to make three rehab starts before rejoining the club while Sale will be evaluated tomorrow as he nears a return to the majors.
Whitlock’s return to the Red Sox, according to Cora, could come with a change of role, as the manager indicated there was “a good chance” that Whitlock would be used in a multi-inning relief role rather than as a member of the rotation. That’s a role that has suited Whitlock quite well throughout his career, as he owns a sterling 2.24 ERA in 112 2/3 innings of work out of the bullpen, a far more impressive figure than his rather pedestrian 4.76 ERA in 19 starts as a member of the rotation.
Even with Whitlock seeming ticketed for the bullpen, the impending returns of Houck and Sale could create a logjam in Boston’s rotation. With the aforementioned trio on the shelf, the club was recently forced to move right-hander Nick Pivetta back into the rotation alongside regular starters James Paxton, Brayan Bello, and Kutter Crawford despite the fact that Pivetta sported a dominant 1.98 ERA in 41 innings coming out of the bullpen since he was removed from the rotation back in May.
With Paxton, Bello, and Sale all likely locked into rotation spots when healthy, the Red Sox will have to pick one of Pivetta, Houck, or Crawford to join Whitlock in the rotation unless the club plans on moving to a six-man rotation upon the return of Sale and Houck to starting action. While Pivetta’s 5.98 ERA coming out of the rotation is the weakest figure of that trio, his 7 1/3 inning, three-run outing in his return to the starting rotation may to have given Red Sox brass renewed confidence in him as a starting option going forward.
More from around MLB’s East divisions…
- Sticking with the Red Sox, outfielder Alex Verdugo was scratched from today’s lineup shortly before the game started. Following the game, Cora briefly discussed Verdugo’s situation with reporters, including Smith. In his comments, Cora indicated that Verdugo’s absence from the lineup was not injury-related. While neither Cora nor Verdugo commented on the specifics of the situation, Cora stressed that it was “the manager’s decision”, saying: “We need everybody available. I decided the reason that he didn’t play. But he wasn’t available today. He was ready to play but he wasn’t available. … The manager decided not to play him today. And he has his reason. I’m not going to go into details or whatever.” After a hot start to the 2023 campaign, Verdugo has slashed just .157/.245/.277 in 94 trips to the plate since the start of July.
- Yankees manager Aaron Boone indicated to reporters, including The Athletic’s Chris Kirschner, that “everything is on the table going forward” regarding right-hander Luis Severino, including a move to the bullpen. Once a rising star in the game as a reliable, front of the rotation arm, Severino has struggled massively in 13 starts this season with a 7.74 ERA and 6.56 FIP. Severino has made fifteen appearances out of the bullpen during his career to excellent results. He’s posted a microscopic 0.31 ERA with a 30.6% strikeout rate in 29 1/3 innings of work as a reliever. If Severino were to exit the rotation, that could open up starts for a younger arm like Jhony Brito or Randy Vasquez.
- Sticking to New York, Mets catcher Omar Narvaez indicated to Will Sammon of The Athletic that he would “probably be back next season” when discussing his upcoming $7MM player option for 2024. Narvaez opened the season as the club’s starting catcher but suffered a calf strain early in the season. While Narvaez was on the shelf, youngster Francisco Alvarez emerged as the club’s everyday player behind the plate, leaving Narvaez in a part-time role upon his return. In addition to his diminished role, Narvaez has struggled badly at the plate this season, slashing just .189/.281/.245 with a wRC+ of 54 in 24 games this year.
- The Marlins figure to welcome young right-hander Eury Perez back to the rotation on Monday, according to Craig Mish of the Miami Herald. Perez made his last big league start on July 6 before being optioned to the minors in an effort to manage his innings and keep him fresh for the stretch run. Perez’s return figures to be a significant boost to the Marlins rotation, as he impressed with a 2.36 ERA and 3.70 FIP in eleven starts during his first stint in the majors earlier this season. The Marlins currently sport a 58-54 record and are just half a game out of the final NL Wild Card spot. That spot is currently occupied by the Reds, against whom Perez is slated to make his return on Monday.
Red Sox Notes: Bloom, Deadline Plans, First Base, Sale
A little under three weeks ago, chief baseball officer Chaim Bloom wasn’t yet sure how the Red Sox might approach the trade deadline, or whether not the team might lean more towards buying or selling. Since then, the Sox have been doing their best to force the front office’s hand, winning nine of their last 10 games and moving to a 49-43 record. The Red Sox are two games out of a wild card berth and, despite a competitive AL East and AL playoff picture in general, it looks like Boston will be some kind of factor in the coming weeks and months leading up to October.
That said, Bloom’s overall perspective about the deadline hasn’t entirely changed, though naturally he is happy with how the Sox have been playing.
“I think the this bigger picture of how we’ve gotten here and how it’s come through a lot of progress from a lot of good performances from our long-term core — whether that’s young players or veteran players — is really encouraging in terms of where the arrow is pointing,” Bloom told Chris Cotillo of MassLive.com. “We’re gonna keep that in mind, too. We feel like we’re making a lot of progress and we just want keep layering on more and more positive things toward that ultimate goal of a championship club.”
Bloom was clear that long-term competitiveness is still the front office’s overarching goal, yet competing this season certainly seems possible. The CBO noted that the core’s development “has not only given us a chance to stay in this race in 2023, but I think has made us — and hopefully a lot of people who care about this team — really optimistic about where this is headed longer-term….Obviously what happens in the short-term, on some level we’re gonna need to factor that in and be responsive to it. As long as we keep seeing the things we wanna see from our core guys, that’s obviously something that we’re gonna keep front and center.”
Trade talks have already been ongoing in advance of the August 1 deadline, and Bloom again implied that the Red Sox (like many teams) won’t be clear buyers or sellers. The Sox could try to make deals that fall into either category, or they “might just be baseball trades that help everybody accomplish what they’re trying to accomplish.” While the standings could certainly provide more clarity over the next two weeks, there are enough teams at least on the fringes of contention that Bloom feels “the [trade] conversations are just gonna require more creativity.”
While Bloom didn’t cite any areas of need heading into the deadline apart, Bloom did make a point of saying that the Red Sox weren’t looking for first base help, since the team is happy with its tandem of Triston Casas and (when he isn’t at DH or third base) Justin Turner. It amounts to a vote of confidence in Casas, who has finally started hitting after a lengthy cold streak to begin the season. Casas hit .184/.300/.342 over his first 180 plate appearances, but has since delivered a much improved .297/.383/.515 slash line in his last 115 PA.
Obviously the Red Sox weren’t going to just give up on a former top prospect who is only in his second MLB season, yet Casas’ recent results have helped solidify his place in Boston’s core, and as a contributor to their 2023 plans. “Triston is learning and growing. He’s clearly not a finished product yet, but when you look at the trajectory, he is moving in the right direction here offensively,” Bloom said.
Pitching would also seem to be a target need at the deadline, as while the Red Sox have a lot of injured arms projected to return relatively soon, there isn’t any guarantee that those hurlers will return on schedule, or be effective when they do return. “Just because you have some of those guys that you expect to be back in action in August doesn’t mean you’re not looking to find other ways to help yourself,” Bloom said.
Chris Sale is one of those injured pitchers on the road to recovery, and manager Alex Cora told reporters (including MLB.com’s Ian Browne) that Sale is slated for a bullpen session on Tuesday. Sale suffered a stress reaction in his shoulder blade and will be out until at least the start of August, as per the minimum absence time required by his 60-day IL placement. Since Sale is only starting to throw off a mound now, it seems likely that his ramp-up and rehab work will keep him out for longer than the first week of August. Sale also noted two weeks ago that his injury “isn’t a very common issue” for a pitcher, so it may be a while before a solid rehab plan is finalized.
Red Sox Notes: Deadline Spending, Kennedy, Sale, Injury Updates
The Red Sox have a 41-42 record and are 4.5 games out of a wild card berth as the calendar flips to July, so it remains to be seen whether or not the team is truly a contender for the postseason. In the opinion of Sox team president/CEO Sam Kennedy, “we definitely believe that this group can string a run together and get us back in this thing,” but Kennedy admitted to MassLive.com’s Sean McAdam that “this is obviously not where we want to be. It’s sort of been a tale of two teams, given the streaky nature of our play….Every time we have a great stretch we seem to then falter and fall down.”
With this in mind, Kennedy said that Boston’s first order of business is just to play some consistent baseball, before considering any next steps. “No one’s thinking about the trade deadline right now. We’re just thinking about trying to put ourselves in a position where we’re looking to add to this team,” he said.
Kennedy’s comments are similar to those made by chief baseball officer Chaim Bloom earlier this week, and Kennedy reiterated that upper management has “no concern” over Bloom’s ability to improve the roster, and that Bloom “will have full authority to do what is in the best interest of the organization, short-term and long-term.”
Bloom’s future with the Red Sox has been a topic of some controversy given the team’s relative lack of results over his three-plus seasons in charge of the front office, and the potential end of his contract. According to McAdam, Bloom’s deal is thought to last through at least the 2024 season, which would indicate that Bloom received a five-year contract when he was initially hired by the Sox after the 2019 campaign (unless Bloom has since signed an extension). The Red Sox are 235-232 during Bloom’s tenure, with a trip to the ALCS in 2021 sandwiched between last-place finishes in 2020 and 2022. The Sox are currently in last place again in the AL East, though with the caveat that the club plays in baseball’s hardest division.
Money is apparently not an issue for ownership, as Kennedy stated that “if we’re in position to add to this team as we approach the deadline, there won’t be any hesitation or reservation about” spending beyond the luxury tax line. As per Roster Resource, Boston’s luxury tax number is just shy of $221.3MM, and thus under the $233MM Competitive Balance Tax threshold. Of course, while Kennedy didn’t address this possibility, one would imagine that the Sox might look to stay under the threshold if they do indeed fall out of contention over the next few weeks, given how Bloom’s attempts to both buy and sell at last year’s deadline resulted in a roster that finished with both a losing record and a tax bill.
August 1 is not just deadline day, but also the first day that Chris Sale would be eligible to be activated from the 60-day injured list. Initially played on the 15-day IL on June 2 with right shoulder inflammation, it was soon announced that Sale was suffering from a stress reaction in his shoulder blade, and was facing yet another lengthy IL stint.
The good news is that Sale has been cleared to start throwing, after undergoing another MRI on Thursday. The plan is for Sale to throw every other day for the time being, with the southpaw throwing from 60 feet but not at max effort. Beyond these first steps, Sale’s timeline is still largely undetermined.
“This isn’t a very common issue,” Sale told The Athletic’s Jen McCaffrey and other reporters. “We had a couple guys who were reference points from the past, but again how many times am I going to stand up here and say something freak happened? So obviously, could have been worse, and [I’ve] been through worse. Just happy for today to be able to start this process and get back to doing what I’m supposed to be doing.”
Red Sox manager Alex Cora also updated reporters (including The Boston Globe’s Peter Abraham) on several other injured players. Yu Chang and Richard Bleier will each start a rehab assignment with Double-A Portland this weekend, while Pablo Reyes‘ rehab assignment is slated to begin on Tuesday. John Schreiber has thrown a pair of bullpen sessions and could be nearing a rehab assignment of his own, once he faces hitters during a live batting-practice session.
Zack Kelly also started a throwing program yesterday, which is particularly notable considering that the right-hander underwent an ulnar nerve transposition revision in his right elbow back in early May. There was some optimism at the time that Kelly might be able to return before the end of the season, and while there’s much to be done before this becomes a reality, it’s certainly a good sign that Kelly is already throwing in some limited capacity.
Red Sox Transfer Chris Sale To 60-Day Injured List
The Red Sox announced a series of roster moves today, some of which were previously reported, though some were new developments. Outfielder Adam Duvall has been reinstated from the 60-day injured list while left-hander Joe Jacques has had his contract selected. To open two active roster spots, lefty Matt Dermody has been designated for assignment while infielder Enmanuel Valdéz was optioned to Triple-A. To open one more 40-man roster spot, lefty Chris Sale has been transferred to the 60-day injured list. The Sox informed reporters, including Pete Abraham of the Boston Globe, that Sale has a stress reaction in his shoulder blade. He won’t require surgery but he will be shut down for three to four weeks before being reevaluated.
Sale, 34, was once one of the most dominant pitchers in the league but he has been severely held back by injuries in recent years. He averaged over 200 innings per season from 2012 to 2017 but was held to roughly 150 per year in the two following seasons. He made trips to the injured list in 2018 due to shoulder inflammation then dealt with elbow inflammation the following year. He ultimately required Tommy John surgery in March of 2020, causing him to miss that entire season.
He returned late in 2021 and was able to make nine starts that year. It was hoped he would be set for a return to full-time work in 2022 but he dealt with a stress reaction in his ribs that kept him out until July. He was hit by a comebacker in his second start, fracturing a finger. While on the injured list again, he broke his wrist in a bicycle accident that ended his season.
Here in 2023, it was again hoped that he could perhaps return to a regular starting role. That was the case for a while, as he made 11 starts with a 4.58 ERA, but he landed on the injured list again on June 2 due to shoulder inflammation. He’ll now be ineligible to return until August, though even that seems contingent on a bit of luck in the health department. The aforementioned shutdown period will keep him out of action for most of the rest of June. Even if he’s healthy after that, he’ll need most of July to build back up and go on a rehab assignment.
In the short term, the Red Sox will be figuring out how to proceed without Sale. They have recently been running out a group with veteran James Paxton alongside younger pitchers like Brayan Bello, Garrett Whitlock, Tanner Houck and Kutter Crawford, while struggles from Corey Kluber and Nick Pivetta got both of those guys pushed into the bullpen.
In the long-term, the Sox will have to wonder what they can expect from Sale going forward. He is playing this year on a salary of $27.5MM and will make that same figure next year as part of the extension he and the club signed going into 2019. There’s also a $20MM club option for 2025 with no buyout. Due to his carousel of injuries, he’s pitched just over 100 innings since the end of the 2019 campaign.